• Eyenovia to Present at Upcoming H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference

    Источник: Nasdaq GlobeNewswire / 09 авг 2023 07:00:00   America/Chicago

    NEW YORK, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), an ophthalmic technology company commercializing Mydcombi™ (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5% for mydriasis and developing the Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced management will deliver a presentation and participate in a panel discussion at the H.C. Wainwright 3rd Annual Ophthalmology Day, which is taking place virtually on August 16, 2023. Presentation and panel details are below:

    H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference

    Presentation

    Format:On-Demand
    Time:Beginning at 7:00 AM ET
      

    Panel Discussion

    Format:Live Virtual Discussion
    Title:Novel Front of the Eye Therapies
    Time:10:00 AM ET
      

    The Eyenovia management team will be participating in virtual one-on-one meetings during the event. Investors interested in meeting with Eyenovia at the conference should contact their H.C. Wainwright representative.

    About Eyenovia, Inc.

    Eyenovia, Inc. (NASDAQ: EYEN) is a commercial stage ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics based on its Optejet platform. Eyenovia is currently focused on the commercialization of Mydcombi (tropicamide+phenylephrine ophthalmic spray) for mydriasis, as well as the ongoing late-stage development of medications in the Optejet device for presbyopia and myopia progression (partnered with Bausch+Lomb). For more information, visit Eyenovia.com.

    The Eyenovia Corporate Information slide deck may be found at ir.eyenovia.com/events-and-presentations.

    Eyenovia Contact:
    Eyenovia, Inc.
    John Gandolfo
    Chief Financial Officer
    jgandolfo@eyenovia.com

    Eyenovia Investor Contact:
    Eric Ribner
    LifeSci Advisors, LLC
    eric@lifesciadvisors.com
    (646) 751-4363

    Eyenovia Media Contact:
    Norbert Lowe
    Vice President, Commercial Operations
    Eyenovia
    nlowe@eyenovia.com


    Primary Logo

Опубликовать